Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new US-based AAV manufacturing and innovation business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programmes and genetic medicines platform Oxford Biomedica to invest $50 million to fund… Read More